Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients
Open Access
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. 12, 15-20
Abstract
Lung cancer is still diagnosed at a late stage although novel diagnostic techniques are in use. However, as pharmacogenomics have evolved novel targeted therapies either with tyrosine kinase inhibitors or immunotherapy can be currently used as daily treatment. We present the case of a woman with anaplastic lymphoma-positive expression and programmed death-ligand 1 (PD-L1) 0% score upon diagnosis who underwent therapeutic surgery and represented PD-L1 90% expression, however, without anaplastic lymphoma kinase expression. Transformation of the tumor or new tumor is a question to be answered for this patient and possibly we should try and direct rebiopsies for this group of targeted therapy patients.Keywords
This publication has 20 references indexed in Scilit:
- Tumor molecular profiling of NSCLC patients using next generation sequencingOncology Reports, 2017
- EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%Respiratory Medicine Case Reports, 2017
- Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case seriesRespiratory Medicine Case Reports, 2017
- Endobronchial ultrasound convex probe for lymphoma, sarcoidosis, lung cancer and other thoracic entities. A case seriesRespiratory Medicine Case Reports, 2017
- Radial Endobronchial Ultrasound (EBUS) Guided Suction Catheter-Biopsy in Histological Diagnosis of Peripheral Pulmonary LesionsJournal of Cancer, 2016
- Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancerAmerican Journal of Health-System Pharmacy, 2015
- Liquid-biopsy-Analysen mithilfe zellfreier DNA (cfDNA)Der Pathologe, 2015
- PD-L1 and Survival in Solid Tumors: A Meta-AnalysisPLOS ONE, 2015
- Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of originThe Lancet Oncology, 2015
- Circulating Tumor DNA as a Liquid Biopsy for CancerClinical Chemistry, 2015